UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 219

Sortiert nach

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Annals of oncology, 2016-05, Vol.27 (5), p.920-926

2016

Volltextzugriff (PDF)

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Annals of oncology, 2018-10, Vol.29, p.viii713-viii713

2018

Volltextzugriff (PDF)

VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination

Neuroscience, 2013-03, Vol.232, p.32-44

2013

Volltextzugriff (PDF)

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

Annals of oncology, 2018-11, Vol.29, p.ix175-ix175

2018

Volltextzugriff (PDF)

Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder

The pharmacogenomics journal, 2013-02, Vol.13 (1), p.21-26

2013

Volltextzugriff (PDF)

RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

European journal of cancer (1990), 2016-12, Vol.69, p.S35-S35

2016

Volltextzugriff (PDF)

Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside

European journal of cancer (1990), 2016-12, Vol.69, p.S5-S6

2016

Volltextzugriff (PDF)

Monoclonal antibody-based therapies for hematologic malignancies

Journal of clinical oncology, 1998-11, Vol.16 (11), p.3691-3710

1998

Volltextzugriff (PDF)

Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma

International journal of hematology, 2002-12, Vol.76 (5), p.401-410

Multani, P

2002

Volltextzugriff (PDF)

Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma

Clinical cancer research, 1998-11, Vol.4 (11), p.2599-2604

1998

Volltextzugriff (PDF)

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Journal of clinical oncology, 2002-05, Vol.20 (10), p.2453-2463

2002

Volltextzugriff (PDF)

A phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma

Clinical cancer research, 1999-09, Vol.5 (9), p.2392-2398

1999

Volltextzugriff (PDF)

Non-Hodgkin's lymphoma: review of conventional treatments

Current pharmaceutical biotechnology, 2001-12, Vol.2 (4), p.279

2001

Volltextzugriff (PDF)

Neocortical Dendritic Pathology in Human Partial Epilepsy: A Quantitative Golgi Study

Epilepsia (Copenhagen), 1994-07, Vol.35 (4), p.728-736

1994

Volltextzugriff (PDF)

A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC

Annals of oncology, 2017-09, Vol.28, p.v612-v612

2017

Volltextzugriff (PDF)

P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii106-iii106

2017

Volltextzugriff (PDF)

8LBA - Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside

European journal of cancer (1990), 2016-12, Vol.69, p.S5-S6

2016

Volltextzugriff (PDF)

OA 14.06 Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1783-S1783

2017

Volltextzugriff (PDF)

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

Journal of clinical oncology, 2002-08, Vol.20 (15), p.3262-3269

2002

Volltextzugriff (PDF)

85 - RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

European journal of cancer (1990), 2016-12, Vol.69, p.S35-S35

2016

Volltextzugriff (PDF)

Improved efficacy response attributed to diagnostic selection – Interim results of the phase 1 experience from ALKA-372-001

Annals of oncology, 2016-10, Vol.27, p.vi42-vi42

2016

Volltextzugriff (PDF)

OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S321-S322

2018

Volltextzugriff (PDF)

OS06.4 Identification of novel NTRK fusion in glioneuronal tumors and radiographic response following therapy with an NTRK inhibitor

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii11-iii11

2017

Volltextzugriff (PDF)

Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study

Atherosclerosis, 2014-01, Vol.232 (1), p.86-93

2014

Volltextzugriff (PDF)

Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma

Journal of clinical oncology, 2003-04, Vol.21 (7), p.1263-1270

2003

Volltextzugriff (PDF)

1 – 25 von 219

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(187)
Mit Volltextzugriff
(196)

Publikationsform

Artikel
(213)
Tagungsberichte
(6)

Sprache

Englisch
(219)
Japanisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(137)
Life Sciences & Biomedicine
(72)
Humans
(58)
Physical Sciences
(46)
Physics
(40)
Female
(33)
Male
(32)
Oncology
(28)
Exact Sciences And Technology
(27)
Biological And Medical Sciences
(26)
Animals
(25)
Adult
(24)
Technology
(22)
Physics, Condensed Matter
(21)
Materials Science
(20)
Medical Sciences
(19)
Physics, Applied
(19)
Middle Aged
(18)
Condensed Matter: Electronic Structure, Electrical, Magnetic, And Optical Properties
(16)
Materials Science, Multidisciplinary
(15)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder

RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside

Monoclonal antibody-based therapies for hematologic malignancies

Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma

Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

A phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma

Non-Hodgkin's lymphoma: review of conventional treatments

Neocortical Dendritic Pathology in Human Partial Epilepsy: A Quantitative Golgi Study

A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC

P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions

8LBA - Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside

OA 14.06 Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

85 - RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

Improved efficacy response attributed to diagnostic selection – Interim results of the phase 1 experience from ALKA-372-001

OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

OS06.4 Identification of novel NTRK fusion in glioneuronal tumors and radiographic response following therapy with an NTRK inhibitor

Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study

Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma

Suchergebnisse filtern